Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525504 | 0.96 | CYP19A1 (0.38) | CYP17A1KCNA5SMN1; SMN2BCHECYP3A4 | |
| SCHEMBL2525502 | 0.94 | CYP19A1 (0.36) | CYP17A1KCNA5SMN1; SMN2CYP3A4LMNA | |
| SCHEMBL2523629 | 0.92 | CYP19A1 (0.39) | CYP17A1KCNA5SMN1; SMN2CYP3A4LMNA | |
| SCHEMBL2518698 | 0.92 | CYP17A1 (0.39) | CYP17A1KCNA5SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL2521557 | 0.90 | KCNA5 (0.39) | KCNA5SMN1; SMN2BCHECYP3A4CYP3A5 | |
| SCHEMBL2516959 | 0.90 | KCNA5 (0.44) | CYP17A1KCNA5SMN1; SMN2BCHECYP3A4 | |
| SCHEMBL2521560 | 0.88 | KCNA5 (0.43) | CYP17A1KCNA5SMN1; SMN2BCHECYP3A4 | |
| SCHEMBL2516898 | 0.88 | CYP19A1 (0.38) | CYP17A1KCNA5SMN1; SMN2BCHECYP3A4 | |
| SCHEMBL2523944 | 0.87 | SMN1; SMN2 (0.39) | KCNA5SMN1; SMN2BCHECYP3A4CYP3A5 | |
| SCHEMBL2522077 | 0.87 | BCHE (0.35) | KCNA5SMN1; SMN2BCHECYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251069-A1 | ISOXAZOLE DERIVATIVES FOR USE AS PLANT GROWTH REGULATORS | SYNGENTA CROP PROTECTION LLC (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251069-A1 | ISOXAZOLE DERIVATIVES FOR USE AS PLANT GROWTH REGULATORS | SYNGENTA CROP PROTECTION LLC (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251069-A1 | ISOXAZOLE DERIVATIVES FOR USE AS PLANT GROWTH REGULATORS | SYNGENTA CROP PROTECTION LLC (US) | 2011-10-13 | — | — | US | disclosed |
| US-20070244162-A1 | SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUNDS AS FUNGICIDES | SYNGENTA LIMITED (GB) | 2007-10-18 | — | — | US | disclosed |
| US-20070244162-A1 | SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUNDS AS FUNGICIDES | SYNGENTA LIMITED (GB) | 2007-10-18 | — | — | US | disclosed |
| US-20070244162-A1 | SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUNDS AS FUNGICIDES | SYNGENTA LIMITED (GB) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244162-A1 | SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUNDS AS FUNGICIDES | NOX5, CYP3A5, API5 | CYP17A1 293/4885KCNA5 431/4885SMN1; SMN2 3172/4885 |
| US-20110251069-A1 | ISOXAZOLE DERIVATIVES FOR USE AS PLANT GROWTH REGULATORS | FKBP5, FKBP2, FKBP1B | CYP17A1 991/4885KCNA5 3306/4885SMN1; SMN2 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.